A randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of ABT-594 in patients with diabetic peripheral neuropathic pain

Pain

Volumn 146, Issue 3, 2009, Pages 245-252

  Rowbotham, Michael C ^a   Rachel Duan, W ^b   Thomas, James ^b   Nothaft, Wolfram ^b   Backonja, Misha Miroslav ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b ABBOTT LABORATORIES   (United States)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

Abt 594; Diabetic peripheral neuropathic pain; Neuronal nicotinic acetylcholine receptor (NNR)

Indexed keywords

5 (2 AZETIDINYLMETHOXY) 2 CHLOROPYRIDINE; PLACEBO;

ABNORMAL DREAMING; ADULT; ANALGESIC ACTIVITY; ARTICLE; ASTHENIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC PERIPHERAL NEUROPATHIC PAIN; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; FEMALE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NEUROPATHIC PAIN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VOMITING;

AGED; ANALGESICS, NON-NARCOTIC; AZETIDINES; DATA INTERPRETATION, STATISTICAL; DIABETIC NEUROPATHIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; NICOTINIC AGONISTS; PAIN; PAIN MEASUREMENT; PYRIDINES; SOCIOECONOMIC FACTORS; TREATMENT OUTCOME;

EID: 70350617803     PISSN: 03043959     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pain.2009.06.013     Document Type: Article

References (29)

1. Available at: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/ [accessed 12.5.2009].
2. Arneric S.P., Holladay M., and Williams M. Neuronal nicotinic receptors: a perspective on two decades of drug discovery research. Biochem Pharmacol 74 (2007) 1092-1101
3. Attal N., Cruccu G., Haanpää M., Hansson P., Jensen T.S., Nurmikko T., Sampaio C., Sindrup S., and Wiffen P. EFNS guidelines on pharmacological treatment of neuropathic pain. Eur J Neurol 13 (2006) 1153-1169
4. Bannon A.W., Decker M.W., Curzon P., Buckley M.J., Kim D.J., Radek R.J., Lynch J.K., Wasicak J.T., Lin N.H., Arnold W.H., Holladay M.W., Williams M., and Arneric S.P. ABT-594 [(R)-5-(2-azetidinylmethoxy)-2-chloropyridine]: a novel, orally effective antinociceptive agent acting via neuronal nicotinic acetylcholine receptors: II. In vivo characterization. J Pharmacol Exp Ther 285 (1998) 787-794
5. Bannon A.W., Decker M.W., Holladay M.W., Curzon P., Donnelly-Roberts D., Puttfarcken P.S., Bitner R.S., Diaz A., Dickenson A.H., Porsolt R.D., Williams M., and Arneric S.P. Broad-spectrum, non-opioid analgesic activity by selective modulation of neuronal nicotinic acetylcholine receptors. Science 279 (1998) 77-81
6. Bannon A.W., Decker M.W., Kim D.J., Campbell J.E., and Arneric S.P. ABT-594, a novel cholinergic channel modulator, is efficacious in nerve ligation and diabetic neuropathy models of neuropathic pain. Brain Res 801 (1998) 158-163
7. Decker M.W., Meyer M.D., and Sullivan J.P. The therapeutic potential of nicotinic acetylcholine receptor agonists for pain control. Expert Opin Investig Drugs 10 (2001) 1819-1830
8. Donnelly-Roberts D.L., Puttfarcken P.S., Kuntzweiler T.A., Briggs C.A., Anderson D.J., Campbell J.E., Piattoni-Kaplan M., McKenna D.G., Wasicak J.T., Holladay M.W., Williams M., and Arneric S.P. ABT-594 [(R)-5-(2-azetidinylmethoxy)-2-chloropyridine]: a novel, orally effective analgesic acting via neuronal nicotinic acetylcholine receptors: I. In vitro characterization. J Pharmacol Exp Ther 285 (1998) 777-786
9. Dworkin R.H., O'Connor A.B., Backonja M., Farrar J.T., Finnerup N.B., Jensen T.S., Kalso E.A., Loeser J.D., Miaskowski C., Nurmikko T.J., Portenoy R.K., Rice A.S.C., Stacey B.R., Treede R.D., Turk D.C., and Wallace M.S. Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain 132 (2007) 237-251
10. Dworkin R.H., Turk D.C., Wyrwich K.W., Beaton D., Cleeland C.S., Farrar J.T., Haythornthwaite J.A., Jensen M.P., Kerns R.D., Ader D.N., Brandenburg N., Burke L.B., Cella D., Chandler J., Cowan P., Dimitrova R., Dionne R., Hertz S., Jadad A.R., Katz N.P., Kehlet H., Kramer L.D., Manning D.C., McCormick C., McDermott M.P., McQuay H.J., Patel S., Porter L., Quessy S., Rappaport B.A., Rauschkolb C., Revicki D.A., Rothman M., Schmader K.E., Stacey B.R., Stauffer J.W., von Stein T., White R.E., Witter J., and Zavisic S. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain 9 (2008) 105-121
11. Freynhagen R., Strojek K., Griesing T., Whalen E., and Balkenohl M. Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomised, double-blind, multicentre, placebo-controlled trial of flexible- and fixed-dose regimens. Pain 115 (2005) 254-263
12. Galer B.S., and Jensen M.P. Development and preliminary validation of a pain measure specific to neuropathic pain: the Neuropathic Pain Scale. Neurology 48 (1997) 332-338
13. Genzen J.R., Van Cleve W., and McGehee D.S. Dorsal root ganglion neurons express multiple nicotinic acetylcholine receptor subtypes. J Neurophysiol 86 (2001) 1773-1782
14. Gilron I., and Coderre T.J. Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs 12 (2007) 113-126
15. Goldstein D.J., Lu Y., Detke M.J., Lee T.C., and Iyengar S. Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain 116 (2005) 109-118
16. Holladay M.W., and Decker M.W. Discovery of ABT-594 and related neuronal nicotinic acetylcholine receptor modulators as analgesic agents: medicinal chemistry and biology. Adv Med Chem 5 (2000) 85-113
17. Jensen T.S., Backonja M.M., Hernandez Jimenez S., Tesfaye S., Valensi P., and Ziegler D. New perspectives on the management of diabetic peripheral neuropathic pain. Diab Vasc Dis Res 3 (2006) 108-119
18. Marubio L.M., del Mar Arroyo-Jimenez M., Cordero-Erausquin M., Lena C., Le Novere N., de Kerchove d'Exaerde A., Huchet M., Damaj M.I., and Changeux J.P. Reduced antinociception in mice lacking neuronal nicotinic receptor subunits. Nature 398 (1999) 805-810
19. Meyer M.D. Neuronal nicotinic acetylcholine receptors as a target for the treatment of neuropathic pain. Drug Dev Res 67 (2006) 355-359
20. Picciotto M.R., Caldarone B.J., Brunzell D.H., Zachariou V., Stevens T.R., and King S.L. Neuronal nicotinic acetylcholine receptor subunit knockout mice: physiological and behavioral phenotypes and possible clinical implications. Pharmacol Ther 92 (2001) 89-108
21. Raskin J., Pritchett Y.L., Wang F., D'Souza D.N., Waninger A.L., Iyengar S., and Wernicke J.F. A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. Pain Med 6 (2005) 346-356 [Malden, Mass]
22. Richter R.W., Portenoy R., Sharma U., Lamoreaux L., Bockbrader H., and Knapp L.E. Relief of painful diabetic peripheral neuropathy with pregabalin: a randomized, placebo-controlled trial. J Pain 6 (2005) 253-260
23. Rosenstock J., Tuchman M., LaMoreaux L., and Sharma U. Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial. Pain 110 (2004) 628-638
24. Rueter L, Curzon P, Kohlhaas K, Gauvin D, Honore P, Surowy C, Meyer M. ABT-894, a neuronal nicotinic receptor (NNR) agonist, with an improved therapeutic window in preclinical models of neuropathic pain vs. gastrointestinal (GI) and CNS side effects. In: Proceedings of the society for neuroscience. Washington, DC; 2008.
25. Sorbera L.A., Revel L., Leeson P., and Castañer J. ABT-594. Drug Future 26 (2001) 927-934
26. Surowy C, Anderson D, Puttfarcken P, Bunnelle W, Nielsen E, Ahring P, Dyhring T, Meyer M. ABT-894, a novel neuronal nicotinic receptor (NNR) agonist exhibiting enhanced selectivity for the α4β2 subtype. In: Proceedings of the society for neuroscience. Washington, DC; 2008.
27. Tolle T, Freynhagen R, Versavel M, Trostmann U, Young Jr. JP, Pregabalin for relief of neuropathic pain associated with diabetic neuropathy: a randomized, double-blind study. Eur J Pain [London, England] 2008;12:203-13.
28. Ware JE. SF-36 Health Survey Manual and Interpretation Guide: New England Medical Center, The Health Institute; 1997.
29. Ware J.E. SF-36 Physical and mental health summary scales: a user's manual (1994), New England Medical Center, Boston, MA